Literature DB >> 3021680

Astatine-211: its possible applications in cancer therapy.

I Brown.   

Abstract

The cyclotron-produced radiohalogen, 211At, is eminently suitable as a possible therapeutic radionuclide. It decays by the emission of 6.8 MeV mean energy alpha-particles, which from a radiobiological viewpoint are of near optimal therapeutic LET. This paper reviews developments in the possible application of [211At]astato-labelled molecules as potential anti-tumour agents. Additionally, radio-dosimetric evidence is presented, and its implications for human cancer therapy are discussed.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3021680     DOI： 10.1016/0883-2889(86)90273-x

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum A        ISSN： 0883-2889


  12 in total

1.  Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.

Authors:  Zhuo Zhang; Meili Zhang; Kayhan Garmestani; Vladimir S Talanov; Paul S Plascjak; Barbara Beck; Carolyn Goldman; Martin W Brechbiel; Thomas A Waldmann
Journal:  Blood       Date:  2006-03-28       Impact factor: 22.113

2.  Biodistribution and dosimetry of free 211At, 125I- and 131I- in rats.

Authors:  Johan Spetz; Nils Rudqvist; Eva Forssell-Aronsson
Journal:  Cancer Biother Radiopharm       Date:  2013-06-22       Impact factor: 3.099

3.  Transcriptional response of BALB/c mouse thyroids following in vivo astatine-211 exposure reveals distinct gene expression profiles.

Authors:  Nils Rudqvist; Toshima Z Parris; Emil Schüler; Khalil Helou; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2012-06-14       Impact factor: 3.138

4.  Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.

Authors:  R H Larsen; O S Bruland
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

5.  Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.

Authors:  R H Larsen; O S Bruland; P Hoff; J Alstad; E K Rofstad
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

6.  Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.

Authors:  E Aurlien; R H Larsen; G Kvalheim; O S Bruland
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

7.  Transcriptional response in normal mouse tissues after i.v. (211)At administration - response related to absorbed dose, dose rate, and time.

Authors:  Britta Langen; Nils Rudqvist; Toshima Z Parris; Emil Schüler; Johan Spetz; Khalil Helou; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2015-01-28       Impact factor: 3.138

8.  Transcriptional Response in Mouse Thyroid Tissue after 211At Administration: Effects of Absorbed Dose, Initial Dose-Rate and Time after Administration.

Authors:  Nils Rudqvist; Johan Spetz; Emil Schüler; Toshima Z Parris; Britta Langen; Khalil Helou; Eva Forssell-Aronsson
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

9.  Non-targeted transcriptomic effects upon thyroid irradiation: similarity between in-field and out-of-field responses varies with tissue type.

Authors:  Britta Langen; Nils Rudqvist; Johan Spetz; John Swanpalmer; Khalil Helou; Eva Forssell-Aronsson
Journal:  Sci Rep       Date:  2016-10-25       Impact factor: 4.379

10.  Gene expression signature in mouse thyroid tissue after (131)I and (211)At exposure.

Authors:  Nils Rudqvist; Johan Spetz; Emil Schüler; Britta Langen; Toshima Z Parris; Khalil Helou; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2015-10-22       Impact factor: 3.138
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.